Cabozantinib’s Role in HCC: Later-Line Data & Frontline Questions
- The phase 3 CELESTIAL trial (NCT01908426) has left a significant mark on the hepatocellular carcinoma (HCC) treatment landscape.
- "CELESTIAL is an older study [from] 2018 that investigated cabozantinib—a multi-targeted TKI with anti-VEGF, -AXL, and -MET [properties]—in patients with advanced HCC.
- The CELESTIAL trial, with a diverse patient population primarily from Asia, Europe, and North America, showcased impressive outcomes.
Advances and Challenges in Hepatocellular Carcinoma Treatment
Table of Contents
- Advances and Challenges in Hepatocellular Carcinoma Treatment
- Advances and Challenges in Hepatocellular Carcinoma Treatment
- Introduction
- Key Questions and answers
- 1.what was the significance of the CELESTIAL trial in HCC treatment?
- 2. What were the outcomes of the COSMIC-312 trial?
- 3.How have recent trials influenced the treatment landscape for HCC?
- 4. What are the future opportunities in HCC treatment?
- 5. What are the remaining challenges in determining optimal second-line treatments for HCC?
- Conclusion
Paradigm Shifts and Discoveries in HCC Treatment
The phase 3 CELESTIAL trial (NCT01908426) has left a significant mark on the hepatocellular carcinoma (HCC) treatment landscape. This study, primarily conducted in 2018, centered around evaluating cabozantinib (Cabometyx, also known as XL184) against a placebo in pretreated HCC patients. The trial included patients in the Child-Pugh class A and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with up to 2 prior lines of systemic treatment.
“CELESTIAL is an older study [from] 2018 that investigated cabozantinib—a multi-targeted TKI with anti-VEGF, -AXL, and -MET [properties]—in patients with advanced HCC. [Eligibility criteria included] a liver function criteria [of] Child-Pugh class A, an ECOG performance status of 0 or 1, and receipt of up to 2 prior lines of systemic therapy. The study [evaluated] 60 mg of [once-daily] cabozantinib vs placebo,” explained King.
The CELESTIAL trial, with a diverse patient population primarily from Asia, Europe, and North America, showcased impressive outcomes. Median overall survival (OS) improved to 10.2 months (95% CI, 9.1-12.0) for those on cabozantinib, remarkably better than the 8.0 months (95% CI, 6.8-9.4) in the placebo group. This trial established cabozantinib as a crucial second- and third-line treatment for HCC.
The Contrasting Outcomes of the COSMIC-312 Trial
The COSMIC-312 trial (NCT03755791), which aimed to evaluate cabozantinib plus atezolizumab (Tecentriq) against sorafenib (Nexavar) in the frontline advanced HCC setting, had mixed outcomes. Initially, the study intended to improve progression-free survival (PFS) and OS in two dual primary endpoints. However, the trial was greatly affected by COVID-19, limiting its hope to a primarily Western patient population. In thelobal studies with primarily regional Peter Jensen, MD, noted the troubles that ensued, PFS was significantly improved, but OS did not meet expectations. Demonstrating the diverse demographics of the trials could greatly help to understand why OS factor persisted contrasting the positive benefits of PFS
There is a significant contrast between these two trials in the mechanisms of action and patient demographics, making it a subject of further clarification. For example, the Asian patient population was drastically affected due to COVID-19, limiting contributions to just 9 cases from China due to the pandemic’s initial spread. Nevertheless, the global implications of this substantiate cabozantinib deficiency effects despite
Immune check-point inhibitors (ICI) in HCC.The Journal of Hepato Carcinoid
Mooring to an Evolving Treatment Paradigm
The unveiling of these trials illuminates not only the merits of new and existing treatments but also the hurdles in the field of HCC treatment.
Gentry King
The second-line treatments we have are all post-sorafenib, so there are no prospective, large studies or high-level data to inform oncologists about what the optimal second-line treatment should be after the new SOC has been initiated. There aren’t prospective trials of [1 drug vs another] drug or even placebo in patients who’ve received first-line Atezolizumab plus bevacizumab [Avastin]for example, or first-line STRIDE. That leaves a big gap,
further practical use to the STRIKE regimen adds a bundle of encouragement.
For demonstrating viable options, it becomes clear with the study, Including for first-line Atezolizumab plus bevacizumab approved in 2020, and >Nivolumab [Opdivo] Plus ipilimumab [Yervoy] approved for previously sorafenib.
forming completeness.
New Trials and Future Opportunities
Looking forward, treating HCC involves more rewarding trials. These developments give a look at profound advancement options to both clinician and healthcare stakeholders, and so the symptoms of the patients present a hopeful sign.
- Of leading-edge strategies attempting to strengthen the initial approaches.
Radiation, or Y90 radioembolization
including the launches being seen presently , being gated specially with the EMERALD-Y90 trial for example) - CAR T-cell therapy being foreseen;
- synchronizing pharmacological domains of study, studies show inspiring responses predominantly focused on China
Bispecific antibodies are on the rise
Advances and Challenges in Hepatocellular Carcinoma Treatment
Introduction
Hepatocellular carcinoma (HCC) presents critically important treatment challenges despite ongoing advancements in the medical field. The development of targeted therapies,notably tyrosine kinase inhibitors (TKIs) like cabozantinib,has shifted the treatment paradigm. This article explores these paradigm shifts,contrasting trial outcomes,and future opportunities in HCC management.
Key Questions and answers
1.what was the significance of the CELESTIAL trial in HCC treatment?
Answer:
The phase 3 CELESTIAL trial was pivotal in establishing cabozantinib (Cabometyx) as a key second- and third-line treatment for advanced hepatocellular carcinoma (HCC). This trial evaluated cabozantinib against a placebo in previously treated patients who were in the Child-Pugh class A and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. The study demonstrated a median overall survival (OS) improvement too 10.2 months for cabozantinib-treated patients compared to 8.0 months for those on placebo. Conducted across diverse populations in Asia, Europe, and North America, the CELESTIAL trial highlights cabozantinib’s efficacy in advanced HCC settings [1][2].
2. What were the outcomes of the COSMIC-312 trial?
Answer:
The COSMIC-312 trial aimed to evaluate the efficacy of cabozantinib plus atezolizumab against sorafenib in the frontline treatment of advanced HCC. While this trial showed significant improvement in progression-free survival (PFS), it did not meet the overall survival (OS) expectations. The trial faced challenges due to the COVID-19 pandemic, which skewed patient demographics mostly towards a Western population, limiting contributions from regions like Asia. This highlighted the variations in response due to demographic differences and posed questions about the mechanisms underlying cabozantinib’s actions in combination with immune checkpoint inhibitors [2].
3.How have recent trials influenced the treatment landscape for HCC?
Answer:
Recent trials, including CELESTIAL and COSMIC-312, have significantly influenced HCC treatment by providing robust data on the efficacy of new therapeutic combinations, particularly those involving TKIs and immune checkpoint inhibitors. However, gaps remain in understanding optimal subsequent treatments after the introduction of targeted therapies like Atezolizumab plus bevacizumab. The evolving treatment paradigm emphasizes the need for future research to define best practices and improve outcomes for patients initially treated with current standards of care such as these immunotherapies [3][2].
4. What are the future opportunities in HCC treatment?
Answer:
The future of HCC treatment involves exploring a variety of innovative strategies:
- Radiation Techniques: Studies such as the EMERALD-Y90 trial investigate advanced forms of localized treatment like Y90 radioembolization.
- CAR T-cell Therapy: Although still in early stages, CAR T-cell therapy holds promise for treating HCC.
- Bispecific Antibodies: These are rising in prominence as another therapeutic avenue by targeting multiple pathways involved in HCC progression.
- Cross-Domain studies: Recent studies have shown promising responses, particularly in populations like those in China, suggesting potential areas for additional targeted research.
These strategies reflect the ongoing strides to enhance treatment efficacy and foster more personalized approaches to HCC management.
5. What are the remaining challenges in determining optimal second-line treatments for HCC?
Answer:
Despite advances, there is still a lack of extensive data for guiding optimal second-line treatments following first-line therapies like Atezolizumab plus bevacizumab. There isn’t sufficient comparative data on different therapies for post-first-line treatment settings,particularly in randomized controlled trials.This underscores the necessity for future trials to fill these gaps and support clinicians in making informed treatment decisions [3][2].
Conclusion
The treatment landscape for HCC is rapidly evolving with key trials like CELESTIAL and COSMIC-312 influencing current practices. As research continues, the focus remains on optimizing treatment sequences and exploring novel therapies to improve patient outcomes while addressing existing challenges in care.
Note: The statistics and details provided above are timeless insights into HCC treatment developments as derived from authoritative sources [1][2][3]. These are critical to understanding the ongoing and future advancements in the field.